Journal article
Mechanisms of ADAMTS13 regulation
Abstract
Recombinant ADAMTS13 is currently undergoing clinical trials as a treatment for hereditary thrombotic thrombocytopenic purpura, a lethal microvascular condition resulting from ADAMTS13 deficiency. Preclinical studies have also demonstrated its efficacy in treating arterial thrombosis and inflammation without causing bleeding, suggesting that recombinant ADAMTS13 may have broad applicability as an antithrombotic agent. Despite this progress, we …
Authors
DeYoung V; Singh K; Kretz CA
Journal
Journal of Thrombosis and Haemostasis, Vol. 20, No. 12, pp. 2722–2732
Publisher
Elsevier
Publication Date
December 2022
DOI
10.1111/jth.15873
ISSN
1538-7933